Kairos Pharma CEO to Present at Investment Conference as Company Advances Cancer Drug Targeting Treatment Resistance

Kairos Pharma Ltd. announced that CEO and Chairman John Yu, MD, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York. This presentation provides the company with a platform to communicate its progress and therapeutic approach to the investment community during a critical period of clinical development.

The company's lead candidate, ENV105, represents a novel approach to addressing one of oncology's most persistent challenges: treatment resistance. ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy frequently results in resistance and disease relapse, limiting long-term treatment efficacy across multiple cancer types. By targeting CD105, ENV105 aims to reverse drug resistance and restore the effectiveness of standard therapies, potentially extending treatment options for patients who have developed resistance.

Currently, ENV105 is advancing through clinical trials that address significant unmet medical needs. The drug is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer. These trials represent critical steps in validating the therapeutic approach and expanding treatment possibilities for patients with limited options. The company's strategy utilizes structural biology to overcome both drug resistance and immune suppression in cancer, positioning Kairos Pharma at the forefront of oncology therapeutics innovation.

The presentation at the H.C. Wainwright conference comes as the company seeks to highlight its scientific approach and clinical progress. Investors and stakeholders can access the latest news and updates relating to Kairos Pharma through the company's newsroom at https://ibn.fm/KAPA. The full press release detailing the conference participation is available at https://ibn.fm/mdybH. Kairos Pharma's approach to targeting drug resistance mechanisms represents an important advancement in cancer treatment research, particularly for patients who develop resistance to standard therapies, offering potential new pathways for treatment when conventional options fail.